US EditionPublished • loading... • Updated
Xspray gets CRL over third-party production issues; Oxford Biomedica buys site from Resilience subsidiary
Summary by endpoints.news
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Xspray gets CRL over third-party production issues; Oxford Biomedica buys site from Resilience subsidiary
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Xspray Pharma received a complete response letter for its leukemia treatment Dasynoc ...
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
